Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March

Key Points

• Short interest in Alumis surged **25.3%** in March to 11,230,693 shares, equal to 14.9% of shares sold short and a short‑interest ratio of 5.5 days.
• Analysts are broadly positive: the consensus rating is Moderate Buy with an average price target of $38.60, and several firms (Oppenheimer, Raymond James, Leerink/Guggenheim) recently raised targets or issued buy/strong‑buy ratings.
• Large institutions (Samsara Biocapital, Vanguard, Cormorant, Trium and new stake MPM Bioimpact) have added sizable positions, despite Alumis missing recent revenue and EPS estimates and analysts projecting a -8.51 EPS for the year.

Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 11,230,693 shares, an increase of 25.3% from the March 15th total of 8,963,277 shares. Currently, 14.9% of the shares of the stock are sold short. Based on an average trading volume of 2,042,725 shares, the short-interest ratio is currently 5.5 days.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ALMS shares. Leerink Partners increased their price objective on shares of Alumis from $20.00 to $32.00 and gave the company an "outperform" rating in a research note on Tuesday, January 6th. Oppenheimer increased their price objective on shares of Alumis from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Monday, March 30th. Loop Capital set a $37.00 price objective on shares of Alumis in a research note on Wednesday, January 21st. Guggenheim increased their price objective on shares of Alumis from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Finally, Raymond James Financial initiated coverage on shares of Alumis in a research note on Tuesday, March 10th. They issued a "strong-buy" rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $38.60.

Institutional Investors Weigh In On Alumis

Several large investors have recently made changes to their positions in the business. Samsara Biocapital LLC increased its position in shares of Alumis by 19.9% in the fourth quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company's stock worth $56,188,000 after acquiring an additional 955,614 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Alumis by 18.4% in the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company's stock worth $16,078,000 after acquiring an additional 625,404 shares in the last quarter. Cormorant Asset Management LP increased its position in shares of Alumis by 69.3% in the fourth quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company's stock worth $35,483,000 after acquiring an additional 1,488,200 shares in the last quarter. Trium Capital LLP increased its position in shares of Alumis by 17.9% in the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company's stock worth $12,457,000 after acquiring an additional 474,072 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in shares of Alumis in the fourth quarter worth $23,443,000.

Alumis Price Performance

Shares of ALMS stock opened at $24.16 on Thursday. The firm has a market cap of $3.07 billion, a P/E ratio of -7.90 and a beta of -0.64. Alumis has a 1-year low of $2.76 and a 1-year high of $30.60. The firm's 50-day simple moving average is $25.68 and its 200-day simple moving average is $16.16.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The company had revenue of $1.93 million for the quarter, compared to analysts' expectations of $2.75 million. Analysts expect that Alumis will post -8.51 earnings per share for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.